Medtronic plc revealed plans to divest its patient monitoring solutions business, which accounted for approximately 6% of overall revenue in fiscal 2025. The company expects the divestiture to close by Q3 2026, generating net proceeds of roughly USD 1.2 billion. Management highlighted that the move will enhance core operating margins by an estimated 120 basis points over the next two fiscal years and free up capital for targeted investment in high-growth segments such as neurostimulation and insulin delivery systems.

In 2025 Medtronic completed the acquisition of a robotics platform developer, securing its entry into the robotic-assisted surgery market. The deal valued the target at USD 850 million upfront plus up to USD 150 million in milestone payments. This strategic move adds a modular robotic system designed for general and urologic procedures, projected to contribute USD 200 million in incremental revenue by fiscal 2027. Analysts estimate the global robotic surgery market will reach USD 10 billion by 2030, with Medtronic aiming for a 10% share by that date.

In October 2023, Medtronic introduced Caprosyn™, its fast-absorbing synthetic suture for cardiovascular and peripheral vascular procedures. Early adoption data from 35 leading U.S. hospitals show a 15% reduction in suture-related complications and a 20% faster operative workflow compared to legacy products. Medtronic projects Caprosyn™ sales to exceed USD 100 million in the current fiscal year, with plans to roll out in Europe and Asia Pacific by mid-2026, targeting cardiothoracic surgeons seeking predictable absorption profiles and reduced tissue trauma.